{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:21:17Z","timestamp":1773832877823,"version":"3.50.1"},"reference-count":25,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney Dis"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Background:<\/i><\/b> Tolvaptan is a promising drug for the prevention of contrast-induced acute kidney injury (CI-AKI) because it induces aquaresis without adversely affecting renal hemodynamics. CI-AKI is a major cause of acute renal failure associated with increased morbidity and mortality. <b><i>Objective:<\/i><\/b> To investigate the effectiveness of different doses of tolvaptan for the prevention of CI-AKI. <b><i>Method:<\/i><\/b> Ninety-one consecutive patients with congestive heart failure (CHF) and chronic kidney disease (CKD) were prospectively enrolled as the tolvaptan group in this study (T-group; 7.5-mg: <i>n<\/i> = 42, 15-mg: <i>n<\/i> = 49). In addition, 91 consecutive patients with CHF and CKD were collected retrospectively as a control group (C-group, <i>n<\/i> = 91). All patients received continuous intravenous infusion of isotonic saline, and tolvaptan was administered to the T-group. <b><i>Results:<\/i><\/b> One patient developed CI-AKI in the T-group versus 3 in the C-group (1.1 vs. 3.3%, <i>p<\/i> = 0.61). On the other hand, the change of serum creatinine in the T-group was lower than that in the C-group. Additionally, in the 7.5-mg group, serum creatinine was unchanged up to 72 h after contrast administration, showing a significant difference from the 15-mg group (\u20130.00 \u00b1 0.09 vs. 0.05 \u00b1 0.12 mg\/dL, <i>p<\/i> = 0.009). Similarly, the change of eGFR was significantly smaller in the 7.5-mg group than that in the 15-mg group (0.7 \u00b1 5.4 vs. \u20132.8 \u00b1 5.1 mL\/min\/1.73 m<sup>2<\/sup>, <i>p<\/i> = 0.002). No patient required hemodialysis and there was no prolongation of hospitalization due to exacerbation of heart failure. <b><i>Conclusions:<\/i><\/b> Compared to hydration alone, tolvaptan combined with hydration could be a safer method for preventing CI-AKI while avoiding exacerbation of heart failure, and a dosage of 7.5-mg might be safer than 15-mg.<\/jats:p>","DOI":"10.1159\/000494724","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T22:01:23Z","timestamp":1543528883000},"page":"100-106","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Tolvaptan for the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Heart Failure and Chronic Kidney Disease"],"prefix":"10.1159","volume":"5","author":[{"given":"Kennosuke","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myong\u00a0Hwa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisaki","family":"Amemiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoei","family":"Isomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.035"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00550109"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00150-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000066641"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.147977"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.3.329"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.11.006"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306962"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1590"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.013"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.416"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.068"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00377.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2011.05503.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.153"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.671644"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2011.02830.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001458"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12124"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000106"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.03.024"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00574-9"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-011-6299-3"}],"container-title":["Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/494724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/494724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:07:16Z","timestamp":1745428036000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000494724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,3,20]]},"published-print":{"date-parts":[[2019,3,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000494724","archive":["Portico"],"relation":{},"ISSN":["2296-9381","2296-9357"],"issn-type":[{"value":"2296-9381","type":"print"},{"value":"2296-9357","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]}}}